These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 19211723)

  • 1. Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice.
    Migrenne S; Lacombe A; Lefèvre AL; Pruniaux MP; Guillot E; Galzin AM; Magnan C
    Am J Physiol Regul Integr Comp Physiol; 2009 Apr; 296(4):R929-35. PubMed ID: 19211723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.
    Tam J; Godlewski G; Earley BJ; Zhou L; Jourdan T; Szanda G; Cinar R; Kunos G
    Am J Physiol Endocrinol Metab; 2014 Feb; 306(4):E457-68. PubMed ID: 24381003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity.
    Wang Q; Perrard XD; Perrard JL; Mansoori A; Smith CW; Ballantyne CM; Wu H
    Obesity (Silver Spring); 2011 Mar; 19(3):505-13. PubMed ID: 20885384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice.
    Pang Z; Wu NN; Zhao W; Chain DC; Schaffer E; Zhang X; Yamdagni P; Palejwala VA; Fan C; Favara SG; Dressler HM; Economides KD; Weinstock D; Cavallo JS; Naimi S; Galzin AM; Guillot E; Pruniaux MP; Tocci MJ; Polites HG
    Obesity (Silver Spring); 2011 Oct; 19(10):1923-34. PubMed ID: 21799481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CB(1) antagonism restores hepatic insulin sensitivity without normalization of adiposity in diet-induced obese dogs.
    Kim SP; Woolcott OO; Hsu IR; Stefanoski D; Harrison LN; Zheng D; Lottati M; Kolka C; Catalano KJ; Chiu JD; Kabir M; Ionut V; Bergman RN; Richey JM
    Am J Physiol Endocrinol Metab; 2012 May; 302(10):E1261-8. PubMed ID: 22374758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of adipokines in rimonabant-mediated insulin sensitivity in ob/ob mice.
    Mohapatra J; Sharma M; Singh S; Pandya G; Chatterjee A; Balaraman R; Patel PR; Jain MR
    J Pharm Pharmacol; 2009 Nov; 61(11):1493-8. PubMed ID: 19903374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways.
    Watanabe T; Kubota N; Ohsugi M; Kubota T; Takamoto I; Iwabu M; Awazawa M; Katsuyama H; Hasegawa C; Tokuyama K; Moroi M; Sugi K; Yamauchi T; Noda T; Nagai R; Terauchi Y; Tobe K; Ueki K; Kadowaki T
    J Biol Chem; 2009 Jan; 284(3):1803-12. PubMed ID: 19008231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake.
    Thornton-Jones ZD; Kennett GA; Benwell KR; Revell DF; Misra A; Sellwood DM; Vickers SP; Clifton PG
    Pharmacol Biochem Behav; 2006 Jun; 84(2):353-9. PubMed ID: 16814374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile.
    Poirier B; Bidouard JP; Cadrouvele C; Marniquet X; Staels B; O'Connor SE; Janiak P; Herbert JM
    Diabetes Obes Metab; 2005 Jan; 7(1):65-72. PubMed ID: 15642077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.
    Després JP; Ross R; Boka G; Alméras N; Lemieux I;
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):416-23. PubMed ID: 19112166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
    Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
    Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does rimonabant independently affect free fatty acid and glucose metabolism?
    Triay J; Mundi M; Klein S; Toledo FG; Smith SR; Abu-Lebdeh H; Jensen M
    J Clin Endocrinol Metab; 2012 Mar; 97(3):819-27. PubMed ID: 22170727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-obesity effects of the combined administration of CB1 receptor antagonist rimonabant and melanin-concentrating hormone antagonist SNAP-94847 in diet-induced obese mice.
    Verty AN; Lockie SH; Stefanidis A; Oldfield BJ
    Int J Obes (Lond); 2013 Feb; 37(2):279-87. PubMed ID: 22473329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different transcriptional control of metabolism and extracellular matrix in visceral and subcutaneous fat of obese and rimonabant treated mice.
    Poussin C; Hall D; Minehira K; Galzin AM; Tarussio D; Thorens B
    PLoS One; 2008; 3(10):e3385. PubMed ID: 19030233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat diet.
    Flamment M; Gueguen N; Wetterwald C; Simard G; Malthièry Y; Ducluzeau PH
    Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1162-70. PubMed ID: 19724020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in adiponectin and inflammatory genes in response to hormonal imbalances in female mice and exacerbation of depot selective visceral adiposity by high-fat diet: implications for insulin resistance.
    Zhang H; Chen X; Aravindakshan J; Sairam MR
    Endocrinology; 2007 Dec; 148(12):5667-79. PubMed ID: 17717050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant.
    Hansen HH; Hansen G; Tang-Christensen M; Larsen PJ; Axel AM; Raben A; Mikkelsen JD
    Eur J Pharmacol; 2010 Jun; 636(1-3):88-95. PubMed ID: 20385125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of chronic oral rimonabant administration on energy budgets of diet-induced obese C57BL/6 mice.
    Zhang LN; Gamo Y; Sinclair R; Mitchell SE; Morgan DG; Clapham JC; Speakman JR
    Obesity (Silver Spring); 2012 May; 20(5):954-62. PubMed ID: 22173576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
    Després JP; Golay A; Sjöström L;
    N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.